ÿþ<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"> <html> <head> <meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1"> <title>EASL 2009 - Poster Presentations</title> <link rel="stylesheet" type="text/css" href="style.css"> </head> <body> <table width="750" align="center" border="0" cellspacing="0" cellpadding="0" class="MainTable"> <tr> <td><img src="http://www2.kenes.com/liver-congress/PublishingImages/top760.jpg" width="760" height="181" /></td> </tr> <tr> <td class="content"><h1>Poster Presentations</h1> <P><b>Session Title:</b> CIRRHOSIS AND COMPLICATIONS - a)PATHOPHYSIOLOGY<br><b>Presentation Date:</b> Apr 25, 2009</P><h2 align='left'><b>SORAFENIB DECREASES PORTAL PRESSURE, PORTOSYSTEMIC COLLATERAL BLOOD FLOW AND SPLANCHNIC BLOOD FLOW IN RATS WITH PREHEPATIC PORTAL HYPERTENSION</b></h2> <p align='left'><b>T. Reiberger</b>, B. Angermayr, P. Schwabl, N. Rohr-Udilova, M. Peck-Radosavljevic<br> <em>Gastroenterology & Hepatology, Medical University of Vienna, Vienna, Austria</em></p><br> <p align='justify'><b>Background: </b> Angiogenesis plays a key role in development of portal hypertension (PHT) and represents a potential therapeutic target. We aimed to evaluate the effects of sorafenib, an multiple tyrosine kinase inhibitor on splanchnic hemodynamics in partial portal vein ligated (PPVL) rats. <br><b>Methods: </b> 4 groups of rats were treated orally with sorafenib (Sora; 10mg/kg/day) or placebo (Plac) for 7 days, beginning at the day of PPVL/sham operation (SO), respectively: (1) PPVL-Sora, (2) PPVL-Plac, (3) SO-Sora and (4) SO-Plac. Measurements of mean arterial pressure (MAP), heart rate (HR), portal pressure (PP) and superior mesenterial artery blood flow (SMAF) were performed after 7 days of treatment. Porto-systemic collateral blood flow (PSCBF) was determined by radioactive microspheres. Splanchnic protein expression of CD31 (endothelial cell marker) were determined by western blotting.<br><b>Results: </b> (Table1) PP and PSCBF were both significantly higher in PPVL than in SO rats. Treatment with Sora results in a significant decrease of PP and SMAF in PPVL-Sora compared to PPVL-Plac rats, while MAP remained unaffected. PPVL-Sora had markedly less PSCBF than PPVL-Plac rats. MAP and HR were similar in all groups. Expression of CD31 was significantly reduced in PPVL-Sora compared to PPVL-Plac rats. <br><b>Conclusion: </b> Sorafenib reduces PP, SMAF and PSCBF in rats with prehepatic portal hypertension without cirrhosis and could represent an effective novel approach to treat PHT. <br><br><table border=1> <tr><td width='20%' align='left'> </td> <td width='20%' align='left'><span style='font-weight:normal; font-style:normal'>PPVL-Sora</span></td> <td width='20%' align='left'><span style='font-weight:normal; font-style:normal'>PPVL-Plac</span></td> <td width='20%' align='left'><span style='font-weight:normal; font-style:normal'>SO-Sora</span></td> <td width='20%' align='left'><span style='font-weight:normal; font-style:normal'>SO-Plac</span></td> </tr><tr><td width='20%' align='left'><span style='font-weight:normal; font-style:normal'>MAP (mmHg)</span></td> <td width='20%' align='left'><span style='font-weight:normal; font-style:normal'>81 (± 11)</span></td> <td width='20%' align='left'><span style='font-weight:normal; font-style:normal'>75 (± 7)</span></td> <td width='20%' align='left'><span style='font-weight:normal; font-style:normal'>79 (± 4)</span></td> <td width='20%' align='left'><span style='font-weight:normal; font-style:normal'>76 (± 4)</span></td> </tr><tr><td width='20%' align='left'><span style='font-weight:normal; font-style:normal'>PP (mmHg)</span></td> <td width='20%' align='left'><span style='font-weight:normal; font-style:normal'>10.9 (± 1.6)</span></td> <td width='20%' align='left'><span style='font-weight:normal; font-style:normal'>14.1 (± 1.4)</span></td> <td width='20%' align='left'><span style='font-weight:normal; font-style:normal'>4.6 (± 1.0)</span></td> <td width='20%' align='left'><span style='font-weight:normal; font-style:normal'>4.9 (± 1.6)</span></td> </tr><tr><td width='20%' align='left'><span style='font-weight:normal; font-style:normal'>SMAF (ml/min/100g)</span></td> <td width='20%' align='left'><span style='font-weight:normal; font-style:normal'>3.54 (±0.66)</span></td> <td width='20%' align='left'><span style='font-weight:normal; font-style:normal'>4.50 (±0.53)</span></td> <td width='20%' align='left'><span style='font-weight:normal; font-style:normal'>2.53 (±0.21)</span></td> <td width='20%' align='left'><span style='font-weight:normal; font-style:normal'>2.50 (±0.40)</span></td> </tr><tr><td width='20%' align='left'><span style='font-weight:normal; font-style:normal'>PSCBF (%)</span></td> <td width='20%' align='left'><span style='font-weight:normal; font-style:normal'>43 (± 9)</span></td> <td width='20%' align='left'><span style='font-weight:normal; font-style:normal'>77 (± 15)</span></td> <td width='20%' align='left'><span style='font-weight:normal; font-style:normal'>1.6 (± 0.3)</span></td> <td width='20%' align='left'><span style='font-weight:normal; font-style:normal'>2.4 (± 1.3)</span></td> </tr></table><br><br></p> <br><a href='Session-Category 2a.htm'>Back</a><br> <p>&nbsp;</p> <p>&nbsp;</p></td> </tr> </table> </body> </html>